- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02168686
Safety Dose Finding Study of ADVM-043 Gene Therapy to Treat Alpha-1 Antitrypsin (A1AT) Deficiency (ADVANCE)
Phase 1/2 Study of Intravenous or Intrapleural Administration of a Serotype rh.10 Replication Deficient Adeno-associated Virus Gene Transfer Vector Expressing the Human Alpha-1 Antitrypsin cDNA to Individuals With Alpha-1 Antitrypsin Deficiency
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Alpha-1 Antitrypsin (A1AT) is a major inhibitor of serine proteases and plays an important role in the lung as an inhibitor of neutrophil elastase. A1AT deficiency is associated with decreases in plasma A1AT levels and is associated with an increased risk for developing asthma, emphysema/COPD, and bronchiectasis. Much of the lung damage is thought to be caused by proteolytic damage from neutrophil elastase and other proteases.
ADVM-043 is an investigational gene therapy product (serotype AAVrh.10 vector) expressing human A1AT that is intended to deliver a functional gene to the liver of patients with A1AT deficiency. Study ADVM-043-01 will study up to 4 dose levels in up to 20 patients and assess the hypothesis that a single administration of an AAV vector expressing the human M-type A1AT (i.e., ADVM-043) to patients with A1AT deficiency is safe and results in persistent therapeutic levels of A1AT in blood and alveolar epithelial lining fluid (epithelial lining fluid is only to be collected in subjects who are dosed intrapleurally). The primary endpoint is safety, and changes in plasma A1AT levels at multiple time points up to 52 weeks after dosing. A prophylactic tapering corticosteroid regimen will be used to protect against potential vector induced transaminitis. Subjects will be followed for up to 52 weeks after dosing. Safety and efficacy data from the IV cohorts will be considered when determining whether to proceed to intrapleural administration. After completion of this study, subjects will be asked to enroll in a Long Term Follow Up study.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Florida
-
Gainesville, Florida, United States, 32610
- University of Florida
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Medical University of South Carolina
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
- Capable of providing informed consent
- Alpha1AT genotype of ZZ or Z Null
- Males and females 18 years and older
- Ongoing treatment with A1AT augmentation is not required, however any subject receiving A1AT augmentation therapy must be willing to washout. Washout is defined as at least 8 weeks between last augmentation therapy and pre-treatment plasma A1AT level
- Willing to remain off PAT for at least 3 months following treatment
- Body mass index 18 to 35 kg/m2
- Fertile men and women of childbearing potential must agree to use barrier contraception for 3 months after treatment
Key Exclusion Criteria:
- FEV1 <35 percent of predicted value at the Screening visit
- Receiving systemic corticosteroids or other immunosuppressive medications
- Immunodeficiency disease or evidence of active infection of any type, including human immunodeficiency virus
- Abnormal liver function tests
- Organ transplant recipient or awaiting transplantation
- Participation in another current or previous gene transfer study
- AAVrh.10 neutralizing antibody titer ≥ 1:5
- Female who is pregnant or lactating
- History of alcohol or drug abuse within the past 5 years
- Any history of allergies that may prohibit study-specific investigations
- Receiving an investigational medicinal product or participating in another investigational study within 3 months prior to consent
- Cigarette smoking, or any other tobacco use, e-cigarettes or other recreational inhalant within 1 year of the Screening Visit
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part A: Dose 1
ADVM-043, at the lowest dose of three planned dose levels, of 8E13 total vg (equivalent to 1E12 vg/kg based on an 80-kg patient) administered IV
|
Gene transfer vector administration
Other Names:
|
Experimental: Part A: Dose 2
ADVM-043 at the intermediate dose of three planned dose levels, of 4E14 total vg (equivalent to 5E12 vg/kg based on an 80-kg patient) administered IV
|
Gene transfer vector administration
Other Names:
|
Experimental: Part A: Dose 3
ADVM-043 at the highest dose of three planned dose levels, of 1.2E15 total vg (equivalent to 1.5E13 vg/kg based on an 80-kg patient) administered IV
|
Gene transfer vector administration
Other Names:
|
Experimental: Part A: Dose 4
ADVM-043 administered at a dose that will be determined
|
Gene transfer vector administration
Other Names:
|
Experimental: Part B (optional): Intrapleural administration
ADVM-043 administered intrapleurally at a dose that will be determined
|
Gene transfer vector administration
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment-emergent Adverse Events Related to ADVM-043
Time Frame: From ADVM-043 infusion through End-of-Study visit at 52 weeks
|
Number and proportion of subjects experiencing treatment-related adverse events related to ADVM-043
|
From ADVM-043 infusion through End-of-Study visit at 52 weeks
|
Abnormal Changes in Clinical Laboratory Parameters
Time Frame: From ADVM-043 infusion through End-of-Study visit at 52 weeks
|
Number of participants with ≥1 abnormal shift from Baseline in neutrophil count, hemoglobin, important serum chemistry parameters
|
From ADVM-043 infusion through End-of-Study visit at 52 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in Total Plasma Concentrations of A1AT up to 52 Weeks
Time Frame: At Week 52
|
Change from baseline at Week 24 and Week 52 of total A1At plasma concentration for subjects who did not receive PAT post -dose
|
At Week 52
|
Change in Plasma Concentrations of M-specific A1AT up to 52 Weeks
Time Frame: At Week 52
|
Change from baseline at Week 52 of plasma concentration of M-specific A1AT for subjects who did not receive PAT post-dose Note:
|
At Week 52
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Charlton Strange, MD, Medical University of South Carolina, Charleston, SC, USA
- Principal Investigator: Friedrich Kueppers, MD, Temple University Hospital, Philadelphia, PA, USA
- Principal Investigator: Mark Brantly, MD, University of Florida, Gainesville, FL, USA
- Principal Investigator: Kyle Hogarth, MD, University of Chicago Medical Center, Chicago, IL, USA
- Principal Investigator: Igor Barjakatarevic, MD, Ronald Reagan UCLA Medical Center, Santa Monica, CA, USA
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ADVM-043-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alpha 1-Antitrypsin Deficiency
-
University of FloridaAlpha-1 FoundationEnrolling by invitation
-
Thomayer University HospitalMasaryk UniversityRecruiting
-
Grifols Therapeutics LLCCompletedAlpha₁-Antitrypsin DeficiencyUnited States
-
Michael Campos, MDCSL BehringCompletedAlpha 1 Antitrypsin DeficiencyUnited States
-
University of PittsburghNational Heart, Lung, and Blood Institute (NHLBI)CompletedAlpha 1 Antitrypsin Deficiency | AATDUnited States
-
Washington University School of MedicineNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); N... and other collaboratorsTerminatedLiver Cirrhosis | Alpha-1-antitrypsin DeficiencyUnited States
-
Alnylam PharmaceuticalsTerminatedZZ Type Alpha-1 Antitrypsin Deficiency Liver DiseaseUnited Kingdom
-
Hospices Civils de LyonCompletedChildren With a Deficiency of Alpha-1 AntitrypsinFrance
-
Heidelberg UniversityTerminatedHereditary Emphysema (Alpha 1-antitrypsin Deficiency)Germany
-
Grifols Therapeutics LLCCompletedEmphysema | Alpha 1-antitrypsin Deficiency (AATD)United States
Clinical Trials on ADVM-043
-
Adverum Biotechnologies, Inc.Completed
-
Michael HoelscherLeibniz Institute for Natural Product Research and Infection Biology Hans...CompletedLung Diseases | Mycobacterium Infections | Tuberculosis | Tuberculosis, Pulmonary | Bacterial Infections RespiratoryNetherlands
-
Adverum Biotechnologies, Inc.ParexelActive, not recruitingNeovascular Age-related Macular DegenerationUnited States, France, United Kingdom
-
Michael HoelscherGerman Federal Ministry of Education and Research; German Center for Infection... and other collaboratorsCompletedLung Diseases | Bacterial Infections | Mycobacterium Infections | Tuberculosis | Tuberculosis, PulmonaryGermany
-
Adverum Biotechnologies, Inc.CompletedDiabetic Retinopathy | Diabetic Macular EdemaUnited States, Puerto Rico
-
GreenLight Biosciences, Inc.Withdrawn
-
GlaxoSmithKlineClick-TB ConsortiumRecruiting
-
Adverum Biotechnologies, Inc.CompletedNeovascular Age-related Macular Degeneration | Wet Age-related Macular DegenerationUnited States
-
Adverum Biotechnologies, Inc.Active, not recruitingNeovascular Age-related Macular Degeneration | Wet Age-related Macular DegenerationUnited States
-
Adverum Biotechnologies, Inc.Enrolling by invitationDiabetic Retinopathy | Diabetic Macular EdemaUnited States, Puerto Rico